Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Yttrium-90

Phase 1Radiopharmaceutical

UUniversity Health Network, Toronto

Yttrium-90 is one of 72 small molecule programs targeting Liver Cancer. It is currently in Phase 1.

2

Indications

4

Total Trials

2

Active Trials

71

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver CancerActive, not recruiting

LiverActive, not recruiting

Liver CancerPreclinical

Active, not recruiting

LiverPhase 1

Active, not recruiting

Competition

Competitive Landscape

61 competitors in Liver Cancer

#DrugCompanyPhaseTrials

Blenoxane

Bristol-Myers Squibb

Taxol

Idamycin

Opdivo

Bristol-Myers Squibb

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Eloxatin

Lenvima

Glucophage

Alimta

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Active, not recruiting

Liver

NCT04518748

Q2 2034

Phase 1/2Recruiting

Liver Cancer

NCT06725121

Clinical

Trials by Indication[1]

Liver Cancer2 trials

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Withdrawn·UUniversity of Southern California·N/A·NCT03300401

Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

Recruiting·UUniversity Health Network, Toronto·Phase 1/2·NCT06725121·48 enrolled

Hepatocellular Carcinoma1 trial

Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma

Completed·NNorthwestern University·Phase 1·NCT00846131·24 enrolled

Liver1 trial

A Phase 1 Study of Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT04518748·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Yttrium-90. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Yttrium-90 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Yttrium-90. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 1[1]
Company: UUniversity Health Network, Toronto

Related News